title: Combined Treatment With 131I-MIBG and Sunitinib Induces Remission in a Patient With Metastatic Paraganglioma Due to Hereditary Paraganglioma-Pheochromocytoma Syndrome From an SDHB Mutation.
abstract: A 22-year-old woman with rapidly progressing metastatic paraganglioma due to hereditary paraganglioma-pheochromocytoma syndrome from an SDHB mutation, who recurred after neoadjuvant chemotherapy, was found to be MIBG avid. She was treated with 2 I-MIBG treatments and concurrent sunitinib, achieving a complete response. She was in full remission for 9 months before developing bone metastases.
authors.affiliation: From the Departments of *Diagnostic Imaging and †Medical Oncology, Cross Cancer Institute, Edmonton, Alberta, Canada.
authors.forename: William
authors.initials: W
authors.lastname: Makis
authors.forename: Karey
authors.initials: K
authors.lastname: McCann
authors.forename: Alexander J B
authors.initials: AJ
authors.lastname: McEwan
authors.forename: Michael B
authors.initials: MB
authors.lastname: Sawyer
mesh_terms: D019797:3-Iodobenzylguanidine / Q000008:administration & dosage / Q000627:therapeutic use*; D000310:Adrenal Gland Neoplasms / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D001859:Bone Neoplasms / Q000556:secondary / Q000628:therapy; D059248:Chemoradiotherapy; D005260:Female; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000627:therapeutic use*; D009154:Mutation; D010673:Pheochromocytoma / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D011758:Pyrroles / Q000008:administration & dosage / Q000627:therapeutic use*; D012074:Remission Induction; D013385:Succinate Dehydrogenase / Q000235:genetics*; D000077210:Sunitinib
chemical_list: D007211:Indoles; D011758:Pyrroles; D019797:3-Iodobenzylguanidine; C108095:SDHB protein, human; D013385:Succinate Dehydrogenase; D000077210:Sunitinib